|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-4-6
|
|
pubmed:abstractText |
Perennial allergic rhinitis (PAR) affects children at a young age. Current guidelines recommend intranasal corticosteroids as the first-line treatment in patients with moderate-to-severe or persistent disease or in those who have congestion. In this study, the long-term safety and efficacy of mometasone furoate nasal spray (MFNS) were assessed in children with PAR.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1872-8464
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
651-7
|
|
pubmed:dateRevised |
2011-1-26
|
|
pubmed:meshHeading |
pubmed-meshheading:19233485-Aerosols,
pubmed-meshheading:19233485-Anti-Allergic Agents,
pubmed-meshheading:19233485-Anti-Inflammatory Agents,
pubmed-meshheading:19233485-Beclomethasone,
pubmed-meshheading:19233485-Cerebrospinal Fluid Rhinorrhea,
pubmed-meshheading:19233485-Child,
pubmed-meshheading:19233485-Cosyntropin,
pubmed-meshheading:19233485-Demography,
pubmed-meshheading:19233485-Double-Blind Method,
pubmed-meshheading:19233485-Female,
pubmed-meshheading:19233485-Humans,
pubmed-meshheading:19233485-Hydrocortisone,
pubmed-meshheading:19233485-Male,
pubmed-meshheading:19233485-Nasal Obstruction,
pubmed-meshheading:19233485-Pregnadienediols,
pubmed-meshheading:19233485-Rhinitis, Allergic, Perennial
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis.
|
|
pubmed:affiliation |
Sylvana Research Associates, San Antonio, TX 78229, USA. pratner@sylvanaresearch.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
